Ursodeoxycholic acid for polycystic liver disease

Ursodeoxycholic acid for polycystic liver disease - UDCA for PLD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012865

Enrollment

100

Registered

2014-03-01

Start date

2014-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic liver disease, polycystic kidney disease

Interventions

UDCA 600mg/day standard treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: presence of abnormality of biliary enzyme caused by polycystic liver.

Exclusion criteria

Exclusion criteria: Patients with jaundice (T-Bil>2.0mg/dL), complete obstruction of biliary ducts, or fulminant hepatitis. Patients with severe pancrease disease, GB stone, or gastric ulcers. Patients who received hepatic TAE within a year.

Design outcomes

Primary

Measure	Time frame
normalization of biliary enzymes, and decrease the rate of cyst progression.	—

Secondary

Measure	Time frame
improvement of nutrition markers	—

Countries

Japan

Contacts

Public ContactJunichi Hoshino

Toranomon Hospital Nephrology Center

hoshino@toranomon.gr.jp03-3588-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026